Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urology | 7 | 2019 | 17 | 2.450 |
Why?
|
| Malpractice | 5 | 2015 | 10 | 1.660 |
Why?
|
| Prostatic Neoplasms | 8 | 2019 | 104 | 1.080 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 176 | 0.840 |
Why?
|
| Clinical Competence | 2 | 2015 | 248 | 0.810 |
Why?
|
| Prostate | 6 | 2019 | 34 | 0.740 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2012 | 33 | 0.670 |
Why?
|
| Kidney Neoplasms | 4 | 2018 | 80 | 0.650 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 11 | 0.650 |
Why?
|
| Ureteral Neoplasms | 1 | 2019 | 7 | 0.650 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2018 | 49 | 0.640 |
Why?
|
| SEER Program | 4 | 2013 | 41 | 0.620 |
Why?
|
| Ureteroscopy | 1 | 2018 | 8 | 0.610 |
Why?
|
| Ureteral Calculi | 1 | 2018 | 7 | 0.610 |
Why?
|
| Kidney Calculi | 1 | 2018 | 8 | 0.610 |
Why?
|
| Simulation Training | 2 | 2019 | 38 | 0.590 |
Why?
|
| Stents | 1 | 2018 | 86 | 0.580 |
Why?
|
| Internship and Residency | 2 | 2018 | 218 | 0.560 |
Why?
|
| Models, Educational | 1 | 2017 | 35 | 0.560 |
Why?
|
| Nephrectomy | 3 | 2018 | 40 | 0.520 |
Why?
|
| Image-Guided Biopsy | 3 | 2019 | 39 | 0.450 |
Why?
|
| Prostatectomy | 4 | 2012 | 23 | 0.450 |
Why?
|
| Nephrons | 1 | 2012 | 6 | 0.400 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 12 | 0.400 |
Why?
|
| Urologic Diseases | 1 | 2011 | 5 | 0.390 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 40 | 0.390 |
Why?
|
| Sarcoidosis | 1 | 2011 | 14 | 0.380 |
Why?
|
| Marital Status | 1 | 2010 | 11 | 0.360 |
Why?
|
| Humans | 25 | 2019 | 28573 | 0.360 |
Why?
|
| Insurance, Liability | 1 | 2010 | 1 | 0.350 |
Why?
|
| Testicular Neoplasms | 1 | 2010 | 19 | 0.350 |
Why?
|
| Male | 19 | 2019 | 15403 | 0.340 |
Why?
|
| Middle Aged | 14 | 2019 | 9324 | 0.320 |
Why?
|
| Penile Neoplasms | 1 | 2008 | 2 | 0.300 |
Why?
|
| Lymph Node Excision | 1 | 2008 | 27 | 0.300 |
Why?
|
| Ultrasonography | 2 | 2019 | 244 | 0.270 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2004 | 113 | 0.270 |
Why?
|
| Liability, Legal | 1 | 2006 | 4 | 0.260 |
Why?
|
| Postoperative Complications | 3 | 2018 | 934 | 0.260 |
Why?
|
| Biopsy, Needle | 2 | 2005 | 108 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 1196 | 0.250 |
Why?
|
| Retrospective Studies | 7 | 2018 | 3614 | 0.250 |
Why?
|
| United States | 5 | 2015 | 2201 | 0.250 |
Why?
|
| Pneumothorax | 1 | 2005 | 11 | 0.240 |
Why?
|
| Adenocarcinoma | 2 | 2003 | 145 | 0.240 |
Why?
|
| Unnecessary Procedures | 1 | 2005 | 30 | 0.230 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 7 | 0.230 |
Why?
|
| Female | 9 | 2019 | 15823 | 0.230 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2004 | 16 | 0.220 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 50 | 0.220 |
Why?
|
| Aged | 10 | 2018 | 9344 | 0.220 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 333 | 0.210 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2003 | 1 | 0.210 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 7 | 0.210 |
Why?
|
| Genital Neoplasms, Male | 1 | 2002 | 1 | 0.210 |
Why?
|
| Seminal Vesicles | 1 | 2002 | 2 | 0.210 |
Why?
|
| Rectum | 3 | 2018 | 45 | 0.200 |
Why?
|
| Glycoproteins | 1 | 2003 | 47 | 0.200 |
Why?
|
| Neurilemmoma | 1 | 2002 | 14 | 0.200 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 352 | 0.200 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 53 | 0.190 |
Why?
|
| Adult | 6 | 2018 | 8175 | 0.180 |
Why?
|
| Survival Rate | 2 | 2012 | 356 | 0.170 |
Why?
|
| Time Factors | 2 | 2017 | 1500 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 76 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 89 | 0.160 |
Why?
|
| Fluoroquinolones | 1 | 2018 | 15 | 0.160 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 39 | 0.150 |
Why?
|
| Ovariectomy | 1 | 2018 | 26 | 0.150 |
Why?
|
| Hysterectomy | 1 | 2018 | 22 | 0.150 |
Why?
|
| Ureter | 1 | 2018 | 29 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2018 | 81 | 0.150 |
Why?
|
| Treatment Failure | 1 | 2018 | 163 | 0.150 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 8 | 0.140 |
Why?
|
| Renal Veins | 1 | 2017 | 3 | 0.140 |
Why?
|
| Surgical Stapling | 1 | 2017 | 5 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 32 | 0.140 |
Why?
|
| Renal Artery | 1 | 2017 | 8 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 105 | 0.140 |
Why?
|
| Risk Factors | 3 | 2018 | 2414 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 88 | 0.130 |
Why?
|
| Self Report | 1 | 2017 | 226 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 158 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 376 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2017 | 198 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 2 | 2005 | 15 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1864 | 0.110 |
Why?
|
| Hernia, Inguinal | 1 | 2013 | 23 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 552 | 0.110 |
Why?
|
| Comorbidity | 3 | 2018 | 500 | 0.100 |
Why?
|
| Melanoma | 1 | 2013 | 60 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2012 | 34 | 0.100 |
Why?
|
| Kidney | 1 | 2013 | 175 | 0.100 |
Why?
|
| Genital Diseases, Male | 1 | 2011 | 8 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2012 | 267 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 308 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2010 | 22 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2011 | 109 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2010 | 14 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 180 | 0.090 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 30 | 0.090 |
Why?
|
| Prognosis | 2 | 2010 | 826 | 0.080 |
Why?
|
| Young Adult | 2 | 2017 | 2104 | 0.080 |
Why?
|
| Incidence | 3 | 2018 | 774 | 0.080 |
Why?
|
| Piperazines | 1 | 2010 | 80 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 190 | 0.080 |
Why?
|
| Physical Examination | 2 | 2005 | 119 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 4901 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 772 | 0.060 |
Why?
|
| Cystectomy | 1 | 2006 | 9 | 0.060 |
Why?
|
| Urination Disorders | 1 | 2005 | 5 | 0.060 |
Why?
|
| Auscultation | 1 | 2005 | 5 | 0.060 |
Why?
|
| Pleura | 1 | 2005 | 9 | 0.060 |
Why?
|
| Respiratory Sounds | 1 | 2005 | 9 | 0.060 |
Why?
|
| Case Management | 1 | 2005 | 11 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 28 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 35 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2017 | 3621 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2005 | 67 | 0.060 |
Why?
|
| Biopsy | 2 | 2018 | 220 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2004 | 20 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 34 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2004 | 22 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 520 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 364 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 5 | 0.050 |
Why?
|
| Length of Stay | 1 | 2005 | 330 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 199 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 373 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 1222 | 0.040 |
Why?
|
| Education | 1 | 2019 | 46 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2018 | 36 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 52 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2018 | 52 | 0.040 |
Why?
|
| Lung | 1 | 2018 | 170 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2017 | 85 | 0.040 |
Why?
|
| Arteriovenous Fistula | 1 | 2017 | 12 | 0.030 |
Why?
|
| Ligation | 1 | 2017 | 38 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 372 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 438 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 331 | 0.030 |
Why?
|
| Operative Time | 1 | 2017 | 93 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 320 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 255 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 8 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 15 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 676 | 0.020 |
Why?
|
| Colectomy | 1 | 2010 | 23 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 66 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 496 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 788 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 1811 | 0.010 |
Why?
|